Angela Rhoten
Family · Claremore, OKNPI 1841575230
Payments from drug & device makers
Across 141 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$546
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$502
- Neurocrine Biosciences, Inc.$438
- Johnson & Johnson$337
- Teva Pharmaceuticals USA, Inc.$193
- Lundbeck LLC$139
- plus $325 from 6 others
What the payments were for
- Food & beverage$2,46399%
- Education$171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 25 | $546 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 31 | $502 |
| Neurocrine Biosciences, Inc. | 34 | $438 |
| Johnson & Johnson | 16 | $337 |
| Teva Pharmaceuticals USA, Inc. | 10 | $193 |
| Lundbeck LLC | 8 | $139 |
| AbbVie | 7 | $126 |
| Otsuka America Pharmaceutical, Inc. | 5 | $103 |
| E.r. Squibb & Sons, L.L.C. | 2 | $43 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$501
How this compares
$2,480 in reported general payments places this provider in the 85th percentile of 2,026 family providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 101 | $336,682 |
| Invega TrinzaPaliperidone Palmitate | 27 | $271,606 |
| Abilify MaintenaAripiprazole | 57 | $150,196 |
| AristadaAripiprazole Lauroxil | 42 | $149,828 |
| IngrezzaValbenazine Tosylate | 16 | $128,126 |
| AustedoDeutetrabenazine | 15 | $70,555 |
| VraylarCariprazine Hcl | 24 | $34,951 |
| RexultiBrexpiprazole | 19 | $27,442 |
| Chlorpromazine Hcl | 69 | $9,221 |
| Aripiprazole | 209 | $8,424 |
| Clozapine | 54 | $4,993 |
| Quetiapine Fumarate | 258 | $4,552 |
| Paliperidone ErPaliperidone | 21 | $3,980 |
| Gabapentin | 194 | $3,385 |
| Lurasidone Hcl | 11 | $3,282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $337 | $608,287128 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $103 | $177,63876 claims |
| Alkermes, Inc.Aristada | $546 | $149,82842 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $438 | $128,12616 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Loxapine | $193 | $71,35935 claims |
| AbbVieVraylar | $126 | $34,95124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,026 family providers in Oklahoma.
Other family in Claremore
- April WilcoxOklahoma City$245K
- Jeremy MorganOklahoma City$63K
- Samantha BellingerOklahoma City$39K
- Candy WilliamsTulsa$22K
- Lacey HillOklahoma City$20K
- Shelby WrightStillwater$17K
- Brandy ReevesNorman$17K
- Amanda OblanderYukon$17K
- Julia John SamuelOklahoma City$17K
- Jillian OakleafTulsa$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.